Jordana G Fein, Priya S Vakharia, A Paul Chous, Rutvi Desai, Fabiana Q Silva, Kimberly Reed, Alyson J Berliner, Robert Vitti, Charles C Wykoff
{"title":"Clinical Outcomes in nAMD with Aflibercept 8 mg in the Phase 2 CANDELA Study.","authors":"Jordana G Fein, Priya S Vakharia, A Paul Chous, Rutvi Desai, Fabiana Q Silva, Kimberly Reed, Alyson J Berliner, Robert Vitti, Charles C Wykoff","doi":"10.1016/j.oret.2025.03.023","DOIUrl":null,"url":null,"abstract":"<p><p>In this post hoc analysis of the CANDELA trial, eyes with neovascular age-related macular degeneration treated with aflibercept 8 mg achieved improved anatomic and visual outcomes, suggesting therapeutic benefit compared with aflibercept 2 mg.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.03.023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Clinical Outcomes in nAMD with Aflibercept 8 mg in the Phase 2 CANDELA Study.
In this post hoc analysis of the CANDELA trial, eyes with neovascular age-related macular degeneration treated with aflibercept 8 mg achieved improved anatomic and visual outcomes, suggesting therapeutic benefit compared with aflibercept 2 mg.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
